Interview with Howard Sui, Managing Director, Merck Serono China
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 41 member companies with pharmaceutical R&D capability.
Statistics show that over RMB20 billion was invested by 40 RDPAC members during the 11th Five Years Plan. And nearly one-third of the investment was allocated in the construction of R&D centre. 70% of RDPAC members have established manufacturing facilities in China summing up to 49 in total so far, and 31 R&D centres were established by 17 companies.
Holding the idea of “Healthier China through Innovation”, RDPAC committed to being a valued partner in delivering the “Healthy China 2020” goal to improve the health and quality of life of people in China：
● Providing our high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
● Committed to securing patients timely access to innovative & high quality drugs;
● Achieving highest standard of integrity for ethical research and business practice;
● Contributing to the growth of the biopharmaceutical sector in China;
● Supporting the development of a sustainable healthcare system in China.
RDPAC is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Contact
Rm 506, Office Bldg 1, Landmark Tower, No.8 North Dongsanhuan Rd, Chaoyang District, Beijing 100004, P.R.China
Tel: +86 10 6590 7696
info@rdpac.org
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
MSD China’s Michel Vounastos gives his initial impressions of the opportunities and challenges inherent in the Chinese healthcare market, and highlights how MSD’s offerings are able to address specific gaps…
Could you please give a brief introduction to the ABO and its history? ABO was established in 2005. The CRO business emerged in 2000 in China, and provided services for…
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of…
Liam Condon, Managing Director of Bayer Healthcare China discusses the government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural healthcare, and the company’s…
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these devices. What is your…
Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine that breaking into this…
You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely…
BioSino has experienced many changes since it was first established and has taken on many different forms and functions. Can you provide a brief history of the company and the…
See our Cookie Privacy Policy Here
